Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 16, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 18, 2026
DirectorIndirect holdingOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000947871-26-001038
Filed / recorded
Nov 18, 2026, 10:08 PM UTC
Added to OQRO
Nov 18, 2026, 10:11 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
WINDWARD BIO GROUP AG
Issuer CIK
2145089
Ticker
WWB
Reporting person
ORBIMED ADVISORS LLC
Relationship
Director, 10% owner
Security
Common Shares
Table
Non-derivative (Table I)
Transaction date
Nov 16, 2026
Transaction code
C
Shares / units
1,611,008
Acquired / disposed
Acquired (A)
Shares owned after
6,881,047
Ownership form
Indirect — See footnotes
Amendment
No
Footnotes from the filing
Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.